FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Asset / Drug

TAR-200

Drug and asset intelligence for TAR-200 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Stage: Development stage unavailable

Recent signals(2)

ClinicalAugust 10, 2026

Study of TAR-200 with Cetrelimab vs BCG in High-risk Bladder Cancer

This study aims to compare event-free survival in BCG-naïve high-risk non-muscle invasive bladder cancer patients treated with TAR-200 plus cetrelimab versus TAR-200 alone and intravesical BCG.

ClinicalAugust 10, 2026

TAR-200 and Cetrelimab Study in Muscle-invasive Bladder Cancer Initiated

A clinical trial has been initiated to evaluate the efficacy of TAR-200 in combination with intravenous cetrelimab compared to the standard treatment of concurrent chemoradiotherapy in patients with muscle-invasive bladder cancer.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts

No catalysts indexed for this entity yet.

Indications

Bladder Cancer →

Therapeutic areas

Bladder Cancer →

Oncology →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.